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[57] ABSTRACT 
This invention relates to amino acid derivatives that are 
useful as inhibitors of bacterial collagenase. The com 
pounds of this invention have a general formula: 
1112 R3 R4 
R-P-N-CH-C-N-CH-C-Y 
l H 
0 
l 
R1 
ll 11 
0 0 
wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hy 
droxy or pharmaceutically acceptable salts thereof; R1 
is hydrogen, alkali metal, lower alkyl, phenyl lower 
alkyl, or phenyl, or substituted phenyl wherein the 
substituent is halo, lower alkoxy or lower alkyl or nitro 
or carboxy or cyano, and pharmaceutically acceptable 
salts thereof; R2, R3 and R4 is hydrogen or alkyl; R2 and 
R4 may be the side groups found on the 20 common 
a-amino acids; R3 and R4 may be connected together to 
form an alkylene bridge of from 2 to 4 carbon atoms; Y 
is alkoxy, aryloxy, primary amide, amino acid deriva 
tive or 
‘is l“ 
—N-CH-X 
where R5 and R6 is hydrogen or alkyl; R5 and R6 may be 
connected together to form an alkylene bridge of from 
2 to 4 carbon atoms; X is hydroxyl or pharmaceutically 
acceptable salts thereof, or an amino acid derivative. 
11 Claims, N0 Drawings 
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INHIBITORS OF BACTERIAL COLLAGENASE 
FIELD OF THE INVENTION 
This invention relates to inhibitors of bacterial colla 
genase, and more particularly to amino acid derivatives 
useful for such purposes. 
BACKGROUND OF THE INVENTION 
Collagen is the major extracellular structural protein 
in skin, tendon, bone, cartilage, and connective tissue in 
vertebrates. Collagen ?brils form a structural matrix 
that binds groups of cells together to form tissues. Col 
lagen constitutes about 40 percent of all proteins in the 
body. Once collagen ?bers are formed, they are not 
renewed. Thus, although these ?bers undergo certain 
changes as skin, muscles, bones, joints, blood vessels, 
etc. experience natural processes such as aging; these 
altered collagen ?brils are not repaired or replaced. 
Collagen disease is any one of a group of pathological 
conditions that are clinically distinct and of various 
etiologies. They cause in common, however, wide 
spread and systemic pathologic changes in connective 
tissue formed by collagen. Such diseases include lupus 
erythematosus, dermatomyositis, scleroderma, polyarter 
itis nodosa, thrombotic purpura, rheumatic fever, and 
rheumatoid arthritis. Collagen pathology may be medi 
ated by collagenase, an enzyme that degrades collagen. 
Collagen exists in vivo in the form of a polypeptide 
chain composed of three helical subunits wound about a 
common axis. These molecules polymerize into insolu 
ble ?brils, and exist in tissue in this form. The helical 
structure is resistant to attack by proteolytic, or diges 
tive, enzymes that degrade less-resistant proteins. There 
are, however, natural enzymes including animal col 
lagenases which are capable of cleaving and thereby 
breaking down collagen molecules. 
It has been shown, for example, that collagenase is 
responsible for ulcers appearing after the eye has been 
burned with alkali; collagen comprises the major or 
ganic component of the cornea. Similarly, this relation 
ship exists for other ulcerative conditions of the cornea, 
including viral ulcers, such as herpes simplex, vaccinia; 
bacterial ulcers; degenerative ulcers and ulcers of un 
known origin. 
In mammals, collagenase is one of the key enzymes 
involved in the joint and cartilage destruction of rheu 
matoid arthritis; see for example, Arthritis And Rheuma 
tism, 20 (6): 1231 (1977). The action of mammalian col 
lagenase has also been implicated as a causative factor in 
several other diseases in mammals. These diseases in 
clude periodontal disease, tumor invasiveness, and epi 
dermolysis bullosa; see for example, American Journal of 
Pathologv, 92 (2): 509 (1978) and The New England J0ur~ 
nal of Medicine, 29l(l3):652 (1974). 
Certain of the collagen disorders are bacterially medi 
ated. Corneal melting during bacterial infections is be 
lieved to be caused, in part or in whole, by the digestion 
of corneal collagen due to bacterial collagenase. Cur 
rent treatment involves the use of cysteine which is only 
a weak inhibitor of collagenase. Gangrene is commonly 
caused by Clostridium and bacterial collagenase is 
thought to be important in the progression and conse 
quences of this infection. Thus, pharmaceutical compo 
sitions effective to inhibit bacterial collagenase would 
be useful in preventing or ameliorating certain diseases. 
Additionally, a standard laboratory technique in 
volves the use of commercially-produced bacterial col 
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lagenase to prepare dispersions of cells separated from 
various minced tissue samples. The use of collagenase 
inhibitors in vitro is necessary to stop the action of 
collagenase once suf?cient numbers of cells have been 
released into suspension. Also, affinity column chroma 
tography using a bound collagenase inhibitor may be 
utilized in the puri?cation of collagenase. Thus, effec 
tive collagenase inhibitors have several uses beyond 
that of clinical pharmacology. 
Accordingly, collagenase inhibitors are generally 
useful in ameliorating or preventing pathological condi 
tions in which collagenases play an etiological role. 
US. Pat. No. 4,263,293 to Sundeen et al discloses a 
mammalian collagenase inhibitor having the general 
formula: 
wherein R1 is hydrogen, alkanoyl of 2 to 10 carbon 
atoms or arylcarbonyl; R2 is l-pyrrolidinyl, l-piperidi 
nyl, 4-morpholinyl, l-piperazinyl, or 4-alkyl-l-piperazi 
nyl; R3 is alkyl of 3 to 8 carbon atoms, cycloalkyl, aryl, 
or arylalkyl; and n is an integer of l to 20. This patent 
discloses the use of certain compositions for the treat 
ment of rheumatoid arthritis using these compounds, 
and provides methods for their preparation. 
US. Pat. No. 4,361,574 to Grant et al also discloses a 
mammalian collagenase inhibitor in the form of a 
polyheterocyclic compound having the general for 
mula: 
N S 
Y I (CH2)nC02R 
N 
R1 
wherein R is hydrogen or lower alkyl, R1 is hydrogen, 
lower alkyl, lower alkoxy, triiluoromethyl or halo; and 
n is 1. These compounds and methods for their prepara 
tion are also disclosed in US. Pat. Nos. 4,214,089, and 
3,704,239. 
Certain ulcers and other pathologic conditions in 
volving tissue destruction have been treated by the 
application of a collagenase inhibitor; such as, cysteine, 
acetyl cysteine, ethylene diamine tetraacetic acid (or its 
sodium or calcium salts) and heparin. As taught by US. 
Pat. No. 4,276,284 to Brown, applications repeated 
daily over a course of time are effective in preventing or 
reducing ulceration. 
Thorsett et al in US. Pat. No. 4,316,896 disclose 
converting enzyme inhibitors and antihypertensive 
amino acid derivatives of the formula: 
ii I R’ 
R1—O—-l|’—X—(Cl-l2),,-CH—-?-N (I) 0 Gil-R4 
R2 COgl-l 
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wherein n is 0 or 1; R is hydrogen, lower alkyl, phenyl 
lower alkyl, hydroxy phenyl lower alkyl, hydroxy 
lower alkyl, aminolower alkyl, guanidino lower alkyl, 
imidazoyl lower alkyl, indolyl lower alkyl, mercapto 
lower alkyl, lower alkyl mercapto lower alkyl; R3 is 
hydrogen; R4 is hydrogen, lower alkyl, phenyl lower 
alkyl, hydroxy phenyl lower alkyl, hydroxy lower al 
kyl, amino lower alkyl, guanidino lower alkyl, imidaz 
oyl lower alkyl, indolyl lower alkyl, mercapto lower 
alkyl, lower alkyl mercapto lower alkyl; R3 and R4 may 
be connected together to form an alkylene bridge of 
from 2 to 4 carbon atoms or an alkylene bridge of from 
a 2 to 3 carbon atoms and one sulfur atom; X is O, NR5, S 
where R5:H or lower alkyl; R1 is hydrogen, lower 
alkyl, aralkyl or aryl;and R2 is hydrogen, lower alkyl, 
aralkyl or aryl and pharmaceutically acceptable salts 
thereof. 
US Pat. No. 4,379,146 to Greenlee et a1 discloses a 
substituted phosphonamide and related compounds 
useful as converting enzyme inhibitors and as antihyper 
tensives. Compounds are disclosed of the general for 
mula: 
wherein R1 is alkyl or substituted alkyl of C1-C6 
wherein the substituent is halo, amino, acylamino; aral 
kyl wherein the alkyl is C1-C4 optionally substituted by 
amino or acylamino and wherein the aryl function is 
phenyl or naphthyl optionally substituted by halo or 3 
hydroxyl; or, heteroaralkyl wherein the alkyl is C1-C4 
optionally substituted by amino or acylamino and 
wherein the heteroaryl group can be indolyl or thienyl; 
R2 is H, lower alkyl of C1-C4, aralkyl such as benzyl; 
R3 is lower alkyl of C1-C6 optionally substituted by an 
amino group; R4 is H, lower alkyl of C1-C6, aralkyl 
such as benzyl; and X is (CI-I2),I wherein n is l or 2, 
CH-OCH3, CH—OH, or S. Other phosphonamides 
are taught by US. Pat. Nos. 4,100,275; 4,143,134; and 
4,316,896. 
SUMMARY OF THE INVENTION 
In a composition aspect, the present invention refers 
to a bacterial collagenase inhibitor that is an amino acid 
derivative of the general formula 
wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hy 
droxy or pharmaceutically acceptable salts thereof; R1 
is hydrogen, alkali metal, lower alkyl, phenyl lower 
alkyl, or phenyl, or substituted phenyl wherein the 
substituent is halo, lower alkoxy or lower alkyl or nitro 
or carboxy or cyano, and pharmaceutically acceptable 
salts thereof; R2, R3 and R4 is hydrogen or alkyl; R; and 
R4 may be the side groups found on the 20 common 
a-amino acids; R3 and R4 may be connected together to 
form an alkylene bridge of from 2 to 4 carbon atoms; Y 
25 
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is alkoxy, aryloxy, primary amide, amino acid deriva 
tive or 
where R5 and R6 is hydrogen or alkyl; R5 and R6 may be 
connected together to form an alkylene bridge of from 
2 to 4 carbon atoms; and X is hydroxyl or pharmaceuti 
cally acceptable salts thereof, or an amino acid deriva 
tive. 
In a further composition aspect, this invention relates 
to pharmaceutical compositions wherein the com 
pounds disclosed above comprise the effective ingredi 
ent. In a method of use aspect, the present invention 
relates to the use of compounds as disclosed above for 
the in vivo inhibition of bacterially produced collage 
nase. 
Further aspects of the present invention relate to the 
use of the above-disclosed compounds as a ligand for 
chromatographic packing materials, and as a collage 
nase inhibitor in the preparation of cell dispersions. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Bacterial collagenase is inhibited by amino acid deriv 
atives of the general formula I 
R2 R3 R4 I 
I 
wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hy 
droxy or pharmaceutically acceptable salts thereof; R1 
is hydrogen, alkali metal, lower alkyl, phenyl lower 
alkyl, or phenyl, or substituted phenyl wherein the 
substituent is halo, lower alkoxy or lower alkyl or nitro 
or carboxy or cyano, and pharmaceutically acceptable 
salts thereof; R2, R3 and R4 is hydrogen or alkyl; R; and 
R4 may be the side groups found on the 20 common 
a-amino acids; R3 and R4 may also be connected to 
gether to form an alkylene bridge of from 2 to 4 carbon 
atoms; Y is alkoxy, aryloxy, primary amide, amino acid 
derivative or 
where R5 and R6 is hydrogen or alkyl; R5 and R6 may be 
connected together to form an alkylene bridge of from 
2 to 4 carbon atoms; and X is hydroxyl or pharmaceuti 
cally acceptable salts thereof, or an amino acid deriva 
tive. 
The term “lower alkyl” when used herein and in the 
appended claims includes straight and branched chain 
hydrocarbon radicals having from 1 to about 6 carbon 
atoms. Illustrative examples of which are methyl, ethyl, 
n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, isopentyl 
(isoamyl), n-hexyl, 3-methyl pentyl, 2,3-dimethyl butyl, 
etc. The term “aryl” includes both carbocyclic and 
heterocyclic (that is, containing one or more 0, S, and 
N atoms as ring members) aromatic ring systems which 
may be substituted, for example, with one or more of 
halogen, ?uorine, chlorine, bromine or iodine, tri?uoro 
4,558,034 
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methyl, lower alkyl, lower alkoxy, lower alkanoyloxy, 
carbonyloxyalkyl, nitro, and cyano. Illustrative aro 
matic ring systems are phenyl, napthyl, furyl, thienyl, 
pyrolyl, immidazolyl, pyridyl, pyrimidinyl, indolyl, 
quinolyl, oxazolyl, and isooxazolyl. Lower alkoxy is a 
lower alkyl as de?ned above linked by an ether oxygen 
atom. Examples of lower alkoxy groups are methoxy, 
ethoxy, n-propoxy, n-butoxy, isopropoxy, tert-butoxy 
and so forth. The term “pharmacologically acceptable 
salt” contemplates the usual and customary forms of 
medicaments formulated in a solid or oral dosage form 
for pharmacological purposes. It also includes those 
employed to formulate either in unit dose or multidose 
form, oral and injectable suspensions and solutions, 
either directly or for reconstitution before administra 
tion. 
The compounds of this invention can be utilized to 
block the action of collagenase of bacterial origin in 
mammals, including humans. Thus the compounds of 
this invention can be administered in the form of a phys 
iologically acceptable salt in a physiologically accept 
able vehicle or carrier by injection or in the form of 
tablets or capsules, for example. 
The preferred dosage range of the compositions of 
the present invention is about 5 mg/kg to about 15 
mg/kg. The standard dosage for oral administration 
preferably ranges from 100 to 500 mg, and most prefera 
bly 250-500 mg. Reduced dosages for children and 
infants are preferred. Administration may be repeated 
during a 24-hour period. 
Dosages for administration according to this inven 
tion may be compounded into oral dosage forms such as 
tablets, capsules, and the like. This is done by combining 
the compounds with conventional carriers and other 
excipients, such as magnesium carbonate, magnesium 
stearate, talc, sugar, lactose, pectin, dextrin, starch, 
gelatin, tragacanth, methyl cellulose, sodium carboxy 
methyl cellulose, low melting wax, cocoa butter, and 
the like. Diluents, ?avoring agents, solubilizers, lubri 
cants, suspending agents, binders, tabletdisintegrating 
agents and the like may also be compounded with the 
compositions of the present invention. Active ingredi 
ents may be encapsulated with or without other carri 
ers. In all cases, the proportion of active ingredients in 
these compositions, whether solid or liquid, will be at 
least suf?cient to impart collagenase inhibitory activity 
in vivo after oral or parenteral administration. 
The dosage requirements vary with the particular 
compositions employed, the route of administration, the 
severity of symptoms presented, and the particular sub 
ject being treated. Treatment will generally be initiated 
with small dosages less than the optimum dose of the 
compound. Throughout, the dosage may be increased 
until the optimum effect under the circumstances is 
reached. In general, the tangible embodiments of the 
invention are most desirably administered at a concen 
tration that will generally afford effective results with 
out causing any harmful or deleterious side effects. The 
dose will vary depending on these and other such fac 
tors which a person skilled in the art will recognize. 
The ability of the compounds of the present invention 
to inhibit bacterial collagenase may be demonstrated by 
in vitro testing in an enzyme assay using collagenase 
produced by Clostridium histolyticium, for example. 
The following examples show the preparation of 
representative compounds of the present invention. The 
compounds of the general formula I described above 
can be prepared by the following equation: 
6 
0 R2 R3 R4 
niicl I-IANH cHcNcHcY——E-t-3§—> + ' 2 CHzClZ 
5 I] O 0 
R1 ‘ 
III, where A = Cl“ or CF3COO“ 
R2 R3 R4 
R i1 OH_ I NH CH E N CH h: YOrHZ/Pd I 
OR‘ o 0 
1V 
Compound (III) in a salt form is condensed in an inert 
solvent such as methylene chloride with phosphochlori 
date II in the presence of a base, such as triethylamine, 
to obtain ester IV. Speci?c hydrolysis or hydrogenoly 
sis of ester IV affords the compound of formula I. 
Amino acids such as alanine or their derivatives such as 
alanine benzyl ester may be attached at Y at their (1 
amino group. 
In the general formula I, R; and R4 may be the side 
groups found on the 20 a-amino acids commonly found 
in proteins (also known as the standard amino acids). 
These side groups are well known in the art. See for 
example, FIGS. 4-2 to 4-4 in A. Lehninger, Biochemistry 
2nd Ed., Worth Publishers, Inc. (1975), which ?gures 
are incorporated herein by reference. These side groups 
0 include straight and branched chain alkyl, hydrodroxy 
alkyl, carboxy alkyl, aralkyl, amino alkyl, carboxamide 
alkyl, mercapto alkyl, phenyl alkyl, hydroxy phenyl 
alkyl, guanidino alkyl, imidazoyl alkyl, indolyl alkyl, 
and pyrrolidinyl'. The compounds of the present inven 
tion exhibit enhanced binding characteristics when R2 
and R4 bear these side groups, thereby increasing their 
resemblance to a collagen or other protein fragment. 
Also, speci?c compounds within the generic group 
ing of the present invention are also effective as inhibi 
tors of other bacterial enzymes that degrade collagen, 
such as the elastase produced by the genus Pseudomo 
nas. One example of such an elastase inhibitor is the 
amino acid derivative of the generic formula wherein 
R4=benzyl, and Y=NH2 . 
Products of general formula I have asymmetric car 
bon atoms to which R2, R4 and R6 are attached, when 
R2, R4 and R6 are other than hydrogen. The compounds 
exist in diastereoisomeric forms or racemic mixtures 
thereof. All of these are within the scope of this inven 
tion, the L-isomer with respect to the carbon atom of 
the amino acids is generally preferred. The compounds 
of this invention form basic salts with various inorganic 
and organic bases which are also within the scope of 
this invention. Such salts include ammonium salts, alkali 
metal salts, alkaline earth metal salts, salts with organic 
bases, e. g. dicyclohexylamine, triethylamine and the 
like. The pharmaceutically acceptable salts are pre 
ferred, although other salts are also useful, e.g., in isolat 
ing or purifying the product. 
Contemplated equivalents of the compounds em 
ployed in the compositions of this invention are those 
phosphorous-containing amino acid derivatives which 
are effective to inhibit bacterial collagenase. Because 
the inhibiting effect of the compound, rather than its 
exact chemical structure, is critical to this invention, it 
will be apparent to those skilled in the art that other 
4,558,034 
7 
R-groups can meet the efficacy requirements of the 
present invention. . 
The following examples illustrate representative ex 
amples of formulations of the compounds of the present 
invention. In these examples and throughout the speci? 
cation, parts are by weight unless otherwise indicated. ‘ 
EXAMPLE 1 
Na-(Dibenzylph0sph0ryl)-Glycyl-L-Pr0line Amide 
To a fresh solution of dibenzylphosphochloridate 
prepared from 1.02 ml (4.6 mmoles) of dibenzyl phos 
phite by the method of Atherton et al., J. Chem. Soc., 
1948, 1106-1110, and 0.9 g (8.86 mmoles) of tri?uor 
oacetate salt of glycyl-L-proline amide, 1.11 ml (0.8 
mmoles) of triethylamine is added at 0° C. After 20 h at 
0° C., the reaction mixture is diluted to 150 ml with 
methylene chloride and washed successively with 0.1N 
hydrochloric acid (2X25 ml), water (1 X25 ml), 0.1 N 
sodium hydroxide (2X25 ml), water (2X 30 ml) and 
saturated sodium chloride solution, dried over anhy 
drous sodium sulfate and evaporated yielding 1.4 g 
(84% yield) of Na-(dibenzylphosphoryl-glycyl-L-pro 
line amide, melting point 9l°—95° C. Hl-NMR (CDCl3, 
TMS): 81.7-2.2 (m, 4H, Pro CH2/3,'y); 3.0-3.7 (m, 4H, 
Pro CH28, Gly CH2); 4.1-4.6 (m, 2H, Pro CHa, P-NH 
); 5.05 (d, 4H, PhCHz); 6.3 (broad m, 1H, NH;); 7.3 (m, 
11H, Ph, NHZ). Mass spectrometry (methane chemical 
ionization (m/e): 432 (M+ 1), 450 (M+29), 472 
(M+4l). 
EXAMPLE 2 
Na-(PhosphoryD-Glycyl-L-Proline Amide 
Dipotassium Salt 
Hydrogen gas is bubbled for l h through a mixture of 
0.43 g (l mmole) of Na-(dibenzylphosphoryl)-glycyl-L 
proline amide and 2 ml of 1.0N potassium hydroxide (2 
mmoles) in 10 ml of 50% (v/v) aqueous tetrahydrofuran 
in the presence of 0.22 g of 10% palladium on carbon. 
After removal of catalyst by ?ltration, the ?ltrate is 
partially evaporated, frozen and lyophilized to give 0.3 
g (91%) of the dipotassium salt of Na-phosphoryl-gly 
cyl-L-proline amide. l-ll-NMR (D2O):82.1 (m, 4H, Pro 
CH2B,7); 3.7 (m, 4H, Gly CH2, Pro CH28),4.3(m, 1H, 
Pro CHa). 
EXAMPLE 3 
Na-(Dibenzylphosphoryl)-Glycyl-L-Prolyl-L-Alanine 
Benzyl Ester 
When benzyl-glycyl-L-prolyl-L-alaninate hydro 
chloride is substituted for glycyl-L- proline amide salt in 
Example 1, the identical process affords Na-(dibenzyl 
phosphoryl)-glycyl-L-prolyl-L-alanine benzyl ester 
with yield 82%, melting point 77°-80° C. HlNMR 
(CDCl3) 81.35 (d, 3H, Ala CH3); 1.8-2.2 (m, 4H, Pro 
CHQBQI) 3.2-3.8 (m, 4H, Pro CH2'y, Gly CH2) 3.9-4.3 
(m, 2H, Ala CH, P-NH); 4.6 (m, 1H, Pro CHa), 5-5.3 
(m, 2H, Ph CH2); 7.35 (m, 16 H, Ph, Ala NH); MS 
(m/e): 594 (m+ 1). 
EXAMPLE 4 
Na-(Phosphoryl)-Glycyl-L-Prolyl-L-Alanine 
Tripotassium Salt 
When Na-(dibenzylphosphoryl)-glycyl-L-prolyl-L 
alanine benzyl ester is substituted for Na-(dibenzylphos 
phoryl)-glycyl-L-proline amide with 3 ml of 1.0N po 
tassium hydroxide (3 mmoles) in Example 2 the identi 
cal process affords Na-phosphoryl-glycyl-L-prolyl-L 
30 
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alanine tripotassium salt. Hl-NMR (D20) 81.61 d, 3H, 
Ala CH3), 2.1 (m, 4H, Pro CH2B,'y); 3.7 (m, 4H, Gly 
CH2, Pro CH28); 4.2 (m, 1H, Ala CHa) 4.45 (m, 1H, 
Pro CHa). 
EXAMPLE 5 
Na-(O-Benzy1-P-Ethy1phosphonyl)-Glycyl-L-Pro1yl 
L-Alanine Benzyl Ester 
When O-benzyl-P-ethylphosphochloridate, prepared 
from ethylphosphonate dibenzylester, by the method of 
Petrov et al, 1959, J. Gen. Chem. USSR 29, 1465-1467, 
is substituted for dibenzyl phosphochloridate in Exam 
ple 3, the identical process affords Na-(O-benzyl-ethyl 
phosphonyl)-glycy1-L-prolyl-L-alanine benzyl ester as 
an oil, with yield 65% after puri?cation of the crude 
product by column chromatography [Silica gel, CHC13, 
(2) CH3CN(2): i-PrOH (1)] H1-NMR(CDCl3 TMS) 
80.8-2.2 (m, 8H, P-CH2CH3, Ala CH3, Pro CH2B,y) 
2.9-4.0 (m, 5H, Pro CH28, Gly CH2 (d, 3.6 , P-NH);4.45 
(m, 2H, Pro CH, Ala CH); 5.0 (m, 4H, PhCHg); 7.3 (s, 
10H, Ph) 7.45 (broad m, 1H, Ala, NH). MS (m/ez5l6 
(M+1), 544 (M+-29). 
EXAMPLE 6 
Na-(Ethylphosphonyl)-Glycyl-L-Prolyl-L-Alanine 
Dipotassium Salt 
When N‘1(O-benzyl-P-ethylphosphonyl)-glycyl-L 
prolyl-L-alanine benzyl ester is substituted for Na 
(dibenzylphosphoryl)-glycyl-L-proline amide in Exam 
ple 2 the identical process affords the titled compound 
with 100% yield. Hl-NMR (D20) 80.8-1.75 (m, 12H, P 
CH2CH3, Ala CH3), 2.05 (m, 4H, Pro CH2B,'y), 3.5 (m, 
2H, Pro CHZ8) 3.65 (d, 2H, Gly CH2), 4.15 (m, 1H, Ala 
CH), 4.45 (m, 1H, Pro CHa). 
EXAMPLE 7 
Na-(O-Benzyl-P-iso-Amylphosphonyl)-Glycyl-L-Pro 
lyl-L-Alanine Benzyl Ester 
When iso-amylphosphonate dibenzyl ester is substi 
tuted for ethylphosphonate dibenzyl ester in Example 5 
the identical process affords Na-(O-benzyl-P-iso-amyl 
phosphonyl)-glycyl-L-prolyl-L-alanine benzyl ester as 
an oil, with 40% yield after puri?cation of crude prod 
uct on column chromatography [silica gel, CHCl3(3): 
CH3CN(1): hexane (1): n-ProH(l)]. H1-NMR(CDCl3) 
80.8 (d, 6H, i-Am CH3); 1.25-2.2 (m, 12H, Ala CH3, 
i-Am CH2a,B, CH-y, Pro CH2B,'y); 3.15-3.85 (m, 5H, 
Pro CH28, Gly CH2, P-NH); 4.5 (m, 2H, Pro CHa, Ala 
CHa); 5.0 (d, 2H, PhCHZOP); 5.15 (s, 2H, PhCH2OC); 
7.35 (s, 11H, Ph, Ala NH). MS (m/e) 558 (M+1); 586 
(M+29). 
EXAMPLE 8 
Na-(iso-Amylphosphonyl)-Glycyl-L-Prolyl-L-Alanine 
Dipotassium Salt 
When N“-(O-benzyl-P-iso-amylphosphonyl)-glycyl 
L-prolyl-L-alanine benzyl ester is substituted for Na 
(ethylphosphonyl)-glycyl-L-prolyl-L-alanine benzyl 
ester in Example 6 the identical process affords the 
titled compound with 80% yield. Hl-NMR (D20) 80.75 
((1, 6H, i-Am CH3); 1.2-1.6 (m,5H, i-Am CH2a,B, 
CH'y); 1.95 (m, 4H, Pro CH2B,'y); 3.3-3.68 (m, 5H, 4H, 
Pro CH28, Gly CH1); 3.72-4.4 (m, 3H, Gly, CH2, Pro 
CHa). 
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EXAMPLE 9 
Na-(O-Benzyl-P-n-Decylphosphonyl)-Glycyl-L-Pro 
lyl-L-Alanine Benzyl Ester 
When n-decylphosphonate dibenzyl ester is substi 
tuted for iso-amylphosphonate dibenzyl ester in Exam 
ple 7 the identical process affords the titled compound 
as an oil with 67% yield. Hl-NMR (CDC13) 50.08-2.3 
(m, 28H, N-dec, Ala CH3, Pro CH2B,'y); 3.0-4.0 (m, 5H, 
Pro CHZ‘O‘, Gly CH2, P-NH) 4.4-4.8 (m 2, H, Ala CH, 
Pro CH); 5.05 (d, 2H, PhCHzOP) 5.2 (s, 2H, 
PhCHgOC); 7.3 (s, 10H, Ph); 7.5 (broad s, 1H, Ala NH). 
MS (m/e) 6.28 (M+l), 656 (M+29). 
EXAMPLE 10 
Na-(n-DecylphosphonyD-Glycyl-L-Prolyl-L-Alanine 
Dipotassium Salt 
When Na-(O-Benzyl-P-n-decylphosphonyl)-glycyl 
L-prolyl-L-alanine benzyl ester is substituted for Na-(O 
benzyl-P-iso-amylphosphonyl)-glycyl-L-prolyl-L-ala 
nine benzyl ester in Example 8 the identical process 
affords the titled compound with 89% yield. Hl-NMR 
(D20) 60.75-l.65 (m, 24H, n-decyl, Ala CH3); 1.95 (m, 
4H, Pro CH2B,7); 3.45 (m, 2H, Pro CHZB); 4.0 (m, 1H, 
Ala CHa); 4.25 (m, 1H, Pro CHa). 
EXAMPLE 1 l 
Na-(O-Benzyl-P-iso-Amylphosphonyl)-Glycyl-Glycyl 
L-Proline Benzyl Ester 
When benzyl glycyl-glycyl-L-prolinate hydrochlo 
ride is subsituted for benzyl glycyl-L-prolyl-L-alaninate 
hydrochloride in Example 7 the identical process af 
fords the titled compound as an oil with 33% yield. 
Hl-NMR (CDC13,TMS): 80.8 (d, 6H, i-Am CH3); 
1.3-2.2 (m, 9H, i-Am CH2a,B, CH'y, Pro 
CH2B,y);3.3-4.5 (m, 8H, pro CHgS, CHa, Gly CH2, 
P-NH); 5.0-5.3 (m, 4H, Ph CH2); 7.3 (s, 10H, Ph) 7.6 
(broad m, 1H, Gly NH). MS (m/e): 544 (M+l); 572 
(M+29); 584 (M+41). 
EXAMPLE l2 
Na-(iso-AmylphosphonyD-Glycyl-Glycyl-L-Proline 
Dipotassium Salt 
When Na-(o-benzyl-P-iso-amylphosphonyl)-glycyl 
glycyl-L-proline benzyl ester is substituted for Na-(O 
benzyl-P-n-decylphosphonyl)-glycyl-L-prolyl-L-ala 
nine benzyl ester in Example 10 the identical process 
affords the title compound with 80% yield. Hl-NMR 
(D20) 60.75 (d, 6H, i-Am CH3); 1.2-1.6 (m, 5H, i-Am 
CH2a,B, CH7); 1.95 (m, 4H, Pro CHZBJ); 3.3-3.68 (m, 
4H, Pro CH28, Gly CH2); 3.72-4.4 (m, 3H, Gly CH2, 
Pro CHa). 
EXAMPLE 13 
In a conventional manner, ?ll gelatin capsules with, 
or prepare compressed tablets containing 150, 350 or 
500 mg of Na-(Dibenzylphosphoryl)-Glycyl-L-Prolyl 
L-Alanine benzyl ester per capsule or tablet. Administer 
one to two capsules or tablets three or four times daily 
to an adult in order to treat the effects of a Clostridium 
infection. 
EXAMPLE 14 
Prepare an alcoholic (8§%) mint-?avored and sweet 
ened solution of 500, 750 or 1000 mg of Na-(Ethylphos 
phonyl)-Glycyl-L-Prolyl-L-Alanine Dipotassium Salt 
per ?uid ounce (30 ml). Administer % fluid ounce up to 
30 
50 
55 
60 
65 
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six times daily, or one fluid ounce up to four times daily, 
every four to six hours for the treatment of bacterial 
tissue infection. 
EXAMPLE 15 
The collagenase inhibitors of the present invention 
may also be useful as in vitro reagents in the production 
of unicellular suspensions from tissue samples. 
Under sterile conditions, excise the distal 5 of a rac 
coon tail. With a sterile razor blade scrape the surface of 
the tail in order to remove hairs present thereon. Next 
place the tail portion in a solution of clorox or other 
bleach for approximately 30 minutes in order to dissolve 
any remaining hair or surface contaminants. After re 
moving the tail from this bath, rinse three times serially 
in sterile distilled water. Then dissect away the epider 
mal portion of the tissue sample, and with forceps and a 
sterile scalpel, tease away remaining tissue present. This 
should result in approximately 5 to 15 grams of raccoon 
tail tissue. 
In a sterile petri dish, using scissors and forceps, 
gently mince the tissue into small fragments. Then with 
a magnetic stirring bar and stirrer apparatus place the 
minced tissue in a volume of approximately 20 ml of 
sterile Ringers lactate, and add 10 ml of 0.05% collage 
nase solution. Allow the stir bar to rotate for approxi 
mately 1 hour, or until the tissue sample is sufficiently 
disaggregated. Filter the suspension through sterile 
gauze and isolate further clumps by low speed centrifu 
gation. 
To the supernatant add 5.0 ml of 0.1% collagenase 
inhibitor as disclosed in the present invention, mix thor 
oughly, and then pellet the cells by higher speed centrif 
ugation. Wash by resuspending the cell pellet three 
times with serial recentrifugations, resuspend in sterile 
RPMI 1640 culture solution and add aliquots of appro 
priate volume to cell culturing vessels and incubate. 
EXAMPLE 16 
The bacterial collagense inhibitors of the present 
invention are also useful in the formation of affinity 
chromatography columns to bind collagenase. Affinity 
columns using collagenase inhibitors as a ligand may be 
prepared in the method of Komiyama et al., “Inhibitory 
Effects of Phosphoramidon on Neutral Metalloen 
dopeptidases and its Application on Af?nity Chroma 
tography”, 65(l)352: 357 (1975). One gram of AH 
sepharose 4B is washed with 0.5M NaCl and with water 
is mixed with 77 mg of l-ethyl-3(3-dimethylaminopro 
pyl) carbodiimide hydrochloride and 50 mg of Na-(P 
iso-amylphosphonyl)-Glycyl-L-Prolyl-L-alanine in 5.0 
ml of aqueous solution at pH 5.0. This preparation is left 
at room temperature with gentle stirring for one day. 
After reaction, the gel is packed into a small column 
(1 X5 cm), and washed successively with 10 ml of each 
of the following solutions: 1M NaCl, 0.1M tris-HCl 
containing 1M NaCl, pH 8.0, 50 mM formic acid con 
taining 1M NaCl, pH 3.0; 0.1M tris-HCl containing 1M 
NaCl, pH 8.0; 50 mM tris-HCl, pH 8.0; and then equili 
brated with 10 mM tris-HCl containing 5 mM CaCl;, 
pH 7.0. Under these conditions about 10 micromoles of 
the inhibitor is coupled with 1 ml of swelled gel. Elu 
tions of bacterial collagenase from the column are per 
formed in a conventional manner. 
From the foregoing description, one skilled in the art 
can easily ascertain the essential characteristics of this 
invention, and without departing from the spirit and 
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scope thereof, can make various changes and modi?ca 
tions of the invention to adapt it to various usages and 
conditions. The foregoing preferred speci?c embodi 
ments are, therefore, to be construed as merely illustra 
tive and not limitative of the disclosure in any way 
whatsoever. 
We claim: 
1. A method for inhibiting bacterial collagenase in 
vivo wherein the bacteria are selected from the group 
consisting of Clostridium and Pseudomonas, which 
comprises administering to a human being a collagenase 
inhibiting effective amount of a pharmaceutical compo 
sition including a compound of the formula: 
wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hy 
droxy or pharamceutically acceptable salts thereof; R1 
is hydrogen, alkali metal, lower alkyl, phenyl lower 
alkyl, or phenyl, or substituted phenyl wherein the 
substituent is halo, lower alkoxy or lower alkyl or nitro 
or carboxy or cyano, and pharmaceutically acceptable 
salts thereof; R2, R3 and R4 are hydrogen or alkyl; R; 
and Mara selected from the group consisting of straight 
and branched chain alkyl, hydroxy alkyl, carboxy alkyl, 
aralkyl, amino alkyl, carboxamide alkyl, mercapto al 
kyl, phenyl alkyl, hydroxy phenyl alkyl, guanidino al 
kyl, imidazoyl alkyl, indolyl alkyl, and pyrrolidinyl; R3 
and R4 may be connected together to form an alkylene 
bridge of from 2 to 4 carbon atoms; Y is alkoxy, aryloxy, 
primary amide, alanine benzyl ester or 
where R5 and R6 is hydrogen or alkyl; R5 and R6 may be 
connected together to form an alkylene bridge of from 
2 to 4 carbon atoms; and X is hydroxyl or pharmaceuti 
cally acceptable salts thereof, in admixture with a phar 
maceutically acceptable carrier. 
2. A method according to claim 1, wherein the com 
position is adapted for oral ingestion and is administered 
orally. 
3. A method according to claim 1, wherein the com 
position is adapted for parenteral administration and is 
administered parenterally. 
4. A method according to claim 1, in the form of a 
tablet or capsule. 
5. A method according to claim 1, in the form of an 
aqueous solution. 
20 
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6. A method of inhibiting the action of a bacterial 
collagenase in vitro wherein the bacteria are selected 
from the group consisting of clostridium and Pseudo 
monas, by allowing the collagenase to react with an 
inhibition-effective amount of a compound of the for 
mula: 
wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hy 
droxy or pharmaceutically acceptable salts thereof; R1 
is hydrogen, alkali metal, lower alkyl, phenyl lower 
alkyl, or phenyl, or substituted phenyl wherein the 
substituent is halo, lower alkoxy or lower alkyl or nitro 
or carboxy or cyano, and pharmaceutically acceptable 
salts thereof; R2, R3 and R4 are hydrogen or alkyl; R2 
and R4are selected from the group consisting of straight 
and branched chain alkyl, hydroxy alkyl, carboxy alkyl, 
aralkyl, amino alkyl, carboxamide alkyl, mercapto a1 
kyl, phenyl alkyl, hydroxy phenyl alkyl, guanidino al 
kyl, imidazoyl alkyl, indolyl alkyl, and pyrrolidinyl; R3 
and R4 may be connected together to form an alkylene 
bridge of from 2 to 4 carbon atoms; Y is alkoxy, aryloxy, 
primary amide, alanine benzyl ester or 
ills Re 
-N-C—X 
where R5 and R6 is hydrogen or alkyl; R5 and R6 may be 
connected together to form an alkylene bridge of from 
2 to 4 carbon atoms; and X is hydroxyl or pharmaceuti 
cally acceptable salts thereof, in admixture with a phar 
maceutically acceptable carrier in an appropriate solu 
tion. 
7. The method of claim 6, wherein R=ethyl, 
R1=K+ or H, R2=isoamyl, R3=H, R4 =benzyl, and 
Y = NH2. 
8. The method of claim 1, wherein R=isoamyl, 
R1 =K+ or H, R2=H, R3+R4=—CH2CH2CH2—-, 
and Y=Alanine. 
9. The method of claim 1, wherein R=ethyl, 
R1=K+ or H, R2=H, R3+R4=——CH2CH2CH2—, 
and Y=Alanine. 
10. The method of claim 1, wherein R=isoamyl, 
R1 =benzyl, R2=H, R3+R4=—-—CH2CH2CH2—, and 
Y=Alanine benzyl ester. 
11. The method of claim 1, wherein R=ethyl, 
R1=benzyl, RZ=H, R3+R4=—CH2CH2CH2-, and 
Y=Alanine benzyl ester. 
* * * 1k * 
